Pioglitazone Therapy Targeting Fatigue in Breast Cancer

Summary

The goal of this project is to evaluate the therapeutic potential of pioglitazone (PIO) to target underlying mechanisms that promote muscle fatigue in patients with breast cancer. This represents an off-label use of this compound, both in terms of the patient population and the clinical phenotype targeted. The central research hypothesis of this study is that daily pioglitazone will restore transcriptional downregulation of pathways within skeletal that promote fatigue.

Timeline

Start

2021-12-23

Primary completion

2026-12

Completion

2026-12

Drugs

Indications